Year: 2021

Financial Results Accelerating; Remains On Track to Deliver Over 1EH/s by End of Q1’22 NEW YORK, NY, Dec. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Soluna Holdings, Inc. (Nasdaq: SLNH), a developer of green data centers for cryptocurrency mining and other intensive computing, announced today the release of its November site level financials, business update and outlook. Michael Toporek, CEO of MTI, stated, “Our team delivered another solid month of strong performance. We expect financial results to accelerate over the next several months as we remain on track to deliver over 1EH/s by the end of Q1 next year. That should drive a yearly revenue run-rate exceeding $61 million and cash contribution margin over $40 million. It is extremely gratifying to see our team executing at this level.”  Key Summary Highlights for November...

TORONTO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase the existing subordinated secured loan facility (the “Loan Facility”) from US$15 million to US$25 million. This increase will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation provided that any such advance will be made before February 1, 2022. The Loan Facility is subordinated to the senior facility with SWK Funding LLC (“SWK”) and bears interest at a rate of eight percent (8%) per annum. Subject to the terms of the subordination...

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced four data presentations, including three oral presentations and one poster presentation, evaluating the combination of ublituximab, the Company’s investigational anti-CD20 monoclonal antibody and UKONIQ® (umbralisib), the Company’s inhibitor of PI3K-delta and CKI-epsilon, (U2), as well as U2-based triple combination therapies, including U2 plus TG’s investigational BTK inhibitor TG-1701. Data presentations occurred this past weekend during the 63rd American Society of Hematology (ASH) annual meeting and exposition. Presentation highlights are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to have showcased four presentations this past weekend, including three oral presentations,...

MONTREAL, Dec. 13, 2021 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced that it has entered into a definitive agreement to sell its remaining juvenile products manufacturing facility in Huangshi, China to Ningbo Xihe Children Products Co, Ltd. for gross proceeds of approximately US$4 million. This sale follows the March 2021 disposition by Dorel of its Zhongshan based manufacturing facility and is part of the overall strategic direction of Dorel Juvenile that includes the co-development of innovative new products with a diverse supplier base. “To re-iterate what we stated earlier this year, our strategic direction for Juvenile is to bring a broader product line to market with greater speed and to decrease complexity and improve cash flow. Our strategic direction is also expected to reduce volatility...

Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001) was presented at the 2021 American Society of Hematology (ASH) Annual Meeting, taking place from December 11-14, 2021. The poster, titled, “Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML),” was presented by Maro Ohanian, D.O., Department of Leukemia,...

The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform Interim results from five evaluable patients in ANCHOR study of KUR-502 showed 80% Overall Response Rate and 60% Complete Response at lowest dose levels BUFFALO, N.Y., Dec. 13, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today it will host a virtual Key Opinion Leader (KOL) event today at 9:00am ET to discuss its NKT cell therapy programs. Athenex had previously announced best responses from five patients of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response...

LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of data from the initial seven patients in an investigator-sponsored study of alvelestat in patients with BOS following hematopoietic stem cell transplantation (“HCT”). These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, GA by Annie Im, MD, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA. The Phase 1b/2 study of alvelestat, an oral neutrophil elastase inhibitor (NCT02669251), is being conducted under a Clinical Trial Agreement between Mereo and the National Cancer Institute (“NCI”), part of the National Institutes...

SAN FRANCISCO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Embark Trucks, Inc. (“Embark”), a leading developer of autonomous technology for the trucking industry, today announced its participation in several upcoming industry and investor conferences:Wedbush Electric Vehicle Forum (December 14, 2021) Wells Fargo Tech in Transportation Day (December 16, 2021)About Embark Embark Trucks, Inc., a wholly owned subsidiary of Nasdaq-listed Embark Technology, Inc. (Nasdaq: EMBK), is an autonomous vehicle company building the software powering autonomous trucks, focused on improving the safety, efficiency, and sustainability of the nearly $700 billion a year trucking market. Headquartered in San Francisco, CA since its founding in 2016, Embark is America’s longest-running self-driving truck program. The company partners with some of the largest...

WARSAW, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support as a Double-Diamond sponsor of the International Pediatric Orthopaedic Symposium (IPOS), which took place December 7 – 11 in Orlando, Florida. Over 400 pediatric orthopedic surgeons attended the meeting. IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading educational meeting for pediatric orthopedic surgeons. David Bailey, President and CEO of OrthoPediatrics, commented, “It was great to be back in Orlando for the 17th Annual IPOS meeting! We are fortunate to be able to re-connect with our surgeon customers through in-person meetings. It is evident that there is no substitute for the hands-on learning...